آيا توسيليزوماب بر نتايج باليني بيماران كوويد - 19 تاثير دارد؟ يك متاآناليز از كارآزمايي هاي تصادفي كنترلي

iated with COVID-19. Methods A comprehensive search was conducted across Scopus, PubMed (Medline), Cochrane Library, EMBASE (Elsevier), ClinicalTrials.gov, and Web of Sciences to identify pertinent studies published until May 2022. The primary search terms included "tocilizumab" and "COVID-19". Following the formulation of the search strategy, all identifed studies were screened, and the data extraction process was initiated. Subsequently, the Cochrane risk of bias checklist was employed to eva‎luate the risk of bias. The efects of tocilizumab were assessed utilizing the pooled risk ratio (RR) and the fxed efect model in STATA (version 17). Results In this meta-analysis, we analyzed 17 clinical trial studies to assess the impact of tocilizumab on mortality in patients with COVID-19. The pooled risk ratio (RR) for mortality was 0.93 (RR: 0.93; 95% CI: 0.86, 1.00; I 2 : 72.39%; P value: 0.001). The fndings indicated that tocilizumab use was associated with a 4% increase in ICU hospitalization (RR: 1.04; 95% CI: 0.90, 1.20; I 2 : 0.00%; P value: 0.65). Additionally, tocilizumab administration was linked to a 2% reduction in the requirement for a ventilator (RR: 0.98; 95% CI: 0.90, 1.08; I 2 : 26.87%; P value: 0.16). Conclusion The administration of tocilizumab during the COVID-19 pandemic, prescribed to patients with the virus, exerted a noteworthy impact on reducing outcomes associated with COVID-19. Keywords Tocilizumab, Actemra, COVID-19, Mortality, Systematic review, Evidence synthesi

233094

دانشگاه علوم پزشكي كردستان

پزشكي

پزشكي

دانشگاه علوم پزشكي كردستان

نويسنده مسئول اول دكتر يوسف مرادي، نويسنده مسئول دوم آرمان جهانگيري